SCHEMBL4773380

SCHEMBL4773380

COC(=O)c1cc(-c2ccc(N(Cc3cccc(Cl)c3Cl)S(C)(=O)=O)cc2)oc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.42
MAPT P10636 4/20 0.42
POLB P06746 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 4/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.38
GAA P10253 2/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777409 0.81 ALDH1A1 (0.51) LMNAMAPTPOLBMCOLN3MEN1
SCHEMBL4773377 0.79 EDNRA (0.39) LMNAMAPTPOLBMEN1KMT2A
SCHEMBL4771011 0.78 LMNA (0.49) LMNAMAPTPOLBMCOLN3MEN1
SCHEMBL4777540 0.75 POLB (0.54) LMNAMAPTPOLBMCOLN3MEN1
SCHEMBL4773540 0.74 GAA (0.43) LMNAMAPTPOLBMCOLN3MEN1
SCHEMBL4777553 0.74 ALDH1A1 (0.49) LMNAMAPTPOLBMEN1KMT2A
SCHEMBL4777413 0.73 KDM4E (0.52) LMNAMAPTPOLBMEN1KMT2A
SCHEMBL4771201 0.73 LMNA (0.50) LMNAMAPTPOLBMEN1KMT2A
SCHEMBL4767773 0.73 LMNA (0.49) LMNAMAPTPOLBMCOLN3MEN1
SCHEMBL4767920 0.73 NR1H4 (0.50) LMNAMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 LMNA 1022/4885MAPT 294/4885POLB 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.